CLIMB BIO, INC. Business Combination, Consideration Transferred, Equity Interests Issued and Issuable
CLIMB BIO, INC. (CLYM) reported Business Combination, Consideration Transferred, Equity Interests Issued and Issuable of $41.87 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-25.
Financial Statements › Notes › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation › Business Combination, Consideration Transferred
us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable · last filed 2025-05-14
- CLIMB BIO, INC. business combination, consideration transferred, equity interests issued and issuable for the quarter ending 2024-12-31 was $0.00.
- CLIMB BIO, INC. business combination, consideration transferred, equity interests issued and issuable for the quarter ending 2024-09-30 was $0.00.
- CLIMB BIO, INC. business combination, consideration transferred, equity interests issued and issuable for fiscal 2024 was $41.87M.
| Period end | Business Combination, Consideration Transferred, Equity Interests Issued and Issuable 3 month | Business Combination, Consideration Transferred, Equity Interests Issued and Issuable 6 month | Business Combination, Consideration Transferred, Equity Interests Issued and Issuable 9 month | Business Combination, Consideration Transferred, Equity Interests Issued and Issuable 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $0.00 derived: sum of 2 quarters · filed 2025-03-25 | $41.87M 10-K · filed 2025-03-25 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $41.87M 10-Q · filed 2024-11-12 | ||
| 2024-06-30 | $41.87M 10-Q · filed 2024-08-14 | |||
| 2024-06-27 | $41.87M 10-Q · filed 2025-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |